臨床泌尿器科60巻2号

2006年02月発行

綜説

泌尿器癌の化学予防

著者： 上門康成²

所属機関： ²和歌山県立医科大学医学部泌尿器科

ページ範囲：P.91 - P.99

泌尿器癌に対する化学予防は，疫学的研究，実験研究および種々の化学物質を使った大規模臨床介入試験として世界中で行われている。ターゲットは膀胱癌，前立腺癌，腎癌である。膀胱癌にはビタミン（A，B6，C，E），セレニウム，DFMO，非ステロイド性消炎鎮痛剤（NSAID）などが，前立腺癌ではビタミンA，C，D，E，DFMO，フラボノイド，リコペン，セレニウム，5α還元酵素阻害剤などが，腎癌ではビタミンA，C，D，Eなどが試みられている。泌尿器癌の化学予防について欧米で進められている臨床介入試験を主に紹介し，癌化学予防の現状について言及した。

参考文献

1）厚生労働省統計票データベース：厚生統計要覧（平成12-15年度）第一編 人口・世帯　第二章 人口動態，第1-31表 悪性新生物の死亡数・死亡率（人口10万対），性×主な部位別．

2）藤木博太，菅沼雅美：癌の化学予防―現状と将来．Biotherapy 16：1-9，2002

3）西野輔翼：癌の化学予防とその現況．総合臨床50：3123-3127，2001

4）斉藤　誠，古川欣也，三浦豊章，他：癌の化学予防の臨床試験．Cancer Frontier 3：87-92，2001

5）Hong WK and Sporn MB：Recent advances in chemoprevention of cancer. Science 278：1073-1077, 1997

6）Hong WK, Spitz MR and Lippman SM：Cancer chemoprevention in the 21st century：genetics, risk modeling, and molecular targets. J Clin Oncol 18：9s-18s, 2000

7）Kelloff GJ, Boone CW, Crowell JA, et al：Chemopreventive drug development：Perspectives and progress. Cancer Epidemiol Biomark Prev 3：85-98, 1994

8）Kakizoe T：Chemoprevention of cancer―Focusing on clinical trials. Jpn J Clin Oncol 33：421-442, 2003

9）津金昌一郎：固形癌の疫学．癌の予防研究―生活習慣改善と化学予防―．血液・免疫・腫瘍6：405-409，2001

10）日本泌尿器科学会，膀胱癌取扱い規約委員会：全国膀胱癌患者登録調査報告：昭和57年―昭和62年，症例のまとめ．日泌尿会誌82：1905-1915，1991

11）Kamat AM and Lamm DL：Chemoprevention of urologic cancer. J Urol 161：1748-1760, 1999

12）Evard JP and Bollag W：Konservative behandlung der rezidivierenden harnblasenpapillomatose mit vitamin-A-Saure. Vorlaufige Mitteilung Schweiz med Wschr 102：1880-1883, 1972

13）Kamat AM and Lamm DL：Chemoprevention of bladder cancer. Urol Clin North Am 29：157-168, 2002.

14）Prout GR Jr and Barton BA：13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem（Suppl）161：148-152, 1992

15）Studer UE, Jenzer S, Biedermann C, et al：Adjuvant treatment with a vitamin A analogue（etretinate）after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 28：284-290, 1995

16）Decensi A, Torrisi R, Bruno S, et al：Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomark Prev 9：1071-1078, 2000

17）Byar D and Blackard C：Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage 1 bladder cancer. Urology 10：556-561, 1977

18）Newling DWW, Robinson MRG, Smith PH, et al：Tryptophan metabolites, pyridoxine（vitamin B6）and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomized phase Ⅲ study performed by the EORTC GU Group. Eur Urol 27：110-116, 1995

19）Lamm DL, Riggs DR, Shriver JS, et al：Megadose vitamins in bladder cancer：A double-blind clinical trial. J Urol 151：21-26, 1994

20）Loprinzi CL, Messing EM, O'Fallon JR, et al：Toxicity evaluation of difluoromethylornithine：Doses for chemoprevention trials. Cancer Epidemiol Biomark Prev 5：371-374, 1996

21）垣添忠生：膀胱発がんの抑制とがん予防．図説 膀胱癌の臨床．メジカルヴュー社，東京，pp131-138，1995

22）Moon RC, Kelloff GJ, Detrisac CJ, et al：Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis 14：1487-1489, 1993

23）Kensler TW and Helzlsouer KJ：Oltipraz：clinical opportunities for cancer chemoprevention. J Cell Biochem（Suppl）22：101-107, 1995

24）Gee J, Sabichi AL and Grossman HB：Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol 43：277-286, 2002

25）Lieberman R：Chemoprevention of superficial bladder cancer. Cancer Treat Res 106：237-254, 2001

26）大堀　理，ピーターTスカルディーノ：疫学．前立腺癌の危険因子と予防．早期前立腺癌モノグラム．第1版．ベクトル・コア，東京，pp1-9，2003

27）伊藤晴夫（編）：前立腺癌のすべて．前立腺癌は予防できるか．メジカルヴュー社，東京，pp17-19，1999

28）岩崎　基，津金昌一郎：前立腺癌予防の取り組みについて．日本臨牀63：321-326，2005

29）塚本　定，赤座英之：急増する前立腺癌の予防は可能か？　Bio Clinica 16：42-45，2001

30）Barqawi A, Thompson IA and Crawford ED：Prostate cancer chemoprevention：An overview of united states trials. J Urol 171：S5-S9, 2004

31）Higgins B and Thompson IA：The prostate cancer prevention trial：Current status. J Urol 171：S15-S18, 2004

32）Fleshner NE and Kucuk O：Antioxidant dietary supplements：rationale and current status as chemopreventive agents for prostate cancer. Urology 57（Suppl 4A）：90-94, 2001

33）Mills PK, Beeson WL, Phillips RL, et al：Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64：598-604, 1989

34）Klein EA：Selenium：Epidemiology and basic science. J Urol 171：S50-S53, 2004

35）The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group：The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330：1029-1035, 1994

36）Klein EA, Thompson IM, Lippman SM, et al：SELECT：the next prostate cancer prevention trial. J Urol 166：1311-1315, 2001

37）Steinbach G, Lynch PM, Phillips RKS, et al：The effects of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342：1946-1952, 2000

38）Gupta S, Srivastava M, Ahmad N, et al：Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42：73-78, 2000

39）Lee LM, Pan CC, Cheng CJ, et al：Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hypaerplasia. Anticancer Res 21：1291-1294, 2001

40）Fujita H, Koshida K, Keller ET, et al：Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53：232-240, 2002

41）Liu XH, Kirschenbaum A, Yao S, et al：Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164：820-825, 2000

42）Walczak J, Wood H, Wilding G, et al：Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urology 57（Suppl 4A）：81-85, 2001

43）Kristal AR：Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cancer. J Urol 171：S54-S58, 2004

44）Schwartz GG and Hulka BS：Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 10：1307-1312, 1990

45）Corder EH, Guess HA and Hulka BS：Vitamin D and prostate cancer：a prediagnostic study with stored sera. Cancer Epidemiol Biomark Prev 2：467-472, 1993

46）Chan JM, Giovannucci E, Andersson SO, et al：Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer（Sweeden）. Cancer Causes Control 9：559-566, 1998

47）Giovannucci E：Dietary influences of 1,25（OH）2 vitamin D in relation to prostate cancer：a hypothesis. Cancer Causes Control 9：567-582, 1998

48）Skowronski RJ, Peehl DM and Feldman D：Vitamin D and prostate cancer：1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132：1952-1960, 1993

49）Miller GJ, Stapleton GE, Ferrara JA, et al：The human prostatic carcinoma cell line LNCap expresses biologically active, specific receptors for 1α, 25-dihydroxyvitamin D3. Cancer Res 52：515-520, 1992

50）Zhao XY, Ly LH, Peehl DM, et al：1α, 25-dihydroxyvitamin D3 actions in LNCap human prostate cancer cells are androgen-dependent. Endocrinology 138：3290-3298, 1997

51）Fleshner N, Bagnell PS, Klotz L, et al：Dietary fat and prostate cancer. J Urol 171：S19-S24, 2004

52）Howie BJ and Shultz TD：Dietary and hormonal interrelationships among vegetarian Seventh-Day Adventists and nonvegetarian men. Am J Clin Nutr 42：127-134, 1985

53）Dorgan JF, Judd JT, Longcope C, et al：Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men：a controlled feeding study. Am J Clin Nutr 64：850-855, 1996

54）Pusateri DJ, Roth WT, Ross JK, et al：Dietary and hormonal evaluation of men at different risks for prostate cancer：plasma and fecal hormone-nutrient interrelationships. Am J Clin Nutr 51：371-377, 1990

55）Hsing AW and Comstock GW：Serological precursors of cancer. Serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomark Prev 2：27-32, 1993

56）Kamat AM and Lamm DL：Diet and nutrition in urologic cancer. The West Virginia Medical Journal 96：449-454, 2000

57）Hanash KM, Aquilina JW, Barrett DM, et al：Clinical research priorities in renal cell carcinoma. Cancer 80：999-1001, 1997

58）Lindblad P, Wolk A, Bergstrom R, et al：Diet and risk of renal cell cancer. a population-based case-control study. Cancer Epidemiol Biomark Prev 6：215-223, 1997

59）Van Poppel H, Nilsson S, Algaba F, et al：Precancerous lesions in the kidney. Scand J Urol Nephrol（Suppl）205：136-165, 2000

60）岡本知士，藤岡知昭，堀内三郎：腎癌患者におけるビタミンD代謝の検討―特に血清1α，25-（OH）2D濃度の変動とその臨床的意義について―．日泌尿会誌82：890-899, 1991

61）Fujioka T, Hasegawa M, Ishikura K, et al：Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 160：247-251, 1889

62）Malt RA, Kingsnorth AN, Lamuraglia GM, et al：Chemoprevention and chemotherapy by inhibition of ornithine decarboxylase activity and polyamine synthesis：colonic, pancreatic, mammary, and renal carcinomas. Adv Enzyme Regul 24：93-102, 1985